SCHEMBL2861675

SCHEMBL2861675

Cc1ccc(OCCO)cc1-n1nc2c(c1N)c(=O)[nH]c1ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 3/20 0.42
PARP1 P09874 1/20 0.39
ADORA3 P0DMS8 5/20 0.38
CHEK1 O14757 1/20 0.37
PDGFRB P09619 1/20 0.37
FGFR1 P11362 1/20 0.37
KDR P35968 1/20 0.37
ADORA1 P30542 2/20 0.36
KDM4E B2RXH2 1/20 0.36
CCNK O75909 1/20 0.35
CCND3 P30281 1/20 0.35
GSK3B P49841 1/20 0.35
CDK7 P50613 1/20 0.35
CDK9 P50750 1/20 0.35
CCNH P51946 1/20 0.35
CDK6 Q00534 1/20 0.35
CDK12 Q9NYV4 1/20 0.35
MAOA P21397 1/20 0.35
CTSV O60911 1/20 0.35
CTSL P07711 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2864429 0.87 MAOA (0.40) PDE2APARP1KDM4ECCNKCCND3
SCHEMBL2868559 0.86 ADORA3 (0.47) ADORA3CHEK1ADORA1KDM4E
SCHEMBL2868743 0.85 ADORA3 (0.44) PARP1ADORA3PDGFRBFGFR1KDR
SCHEMBL2867439 0.84 MAOA (0.40) PDE2APARP1CHEK1CCNKCCND3
SCHEMBL2871151 0.83 ADORA3 (0.38) PARP1ADORA3CHEK1ADORA1KDM4E
SCHEMBL2857583 0.82 ADORA3 (0.43) ADORA3CHEK1PDGFRBFGFR1KDR
SCHEMBL2871372 0.82 ADORA3 (0.39) PARP1ADORA3CHEK1ADORA1KDM4E
SCHEMBL2859059 0.82 ADORA3 (0.45) ADORA3CHEK1PDGFRBFGFR1KDR
SCHEMBL2871146 0.82 MAOA (0.36) PDE2APARP1FGFR1CCNKCCND3
SCHEMBL2860215 0.81 PDE2A (0.41) PDE2APARP1FGFR1KDM4EMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 PDE2A 2228/4885PARP1 2258/4885ADORA3 1829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.